LITFULO caps 50 mg 30 pce

7680696950013 Pharmacode 1125770 CH-69695 L04AF08 07.15.0.
LITFULO caps 50 mg 30 pce
LITFULO caps 50 mg 30 pce
LITFULO caps 50 mg 30 pce
1 / 3
google

Details

GTIN
7680696950013
Pharmacode
1125770
Product number
6969501
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
ritlecitinibum 50 mg ut ritlecitinibi tosilas, cellulosum microcristallinum, lactosum monohydricum 21.269 mg, crospovidonum, glyceroli dibehenas, Kapselhülle: hypromellosum, E 171, E 172 (flavum), E 133, Drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, E 172 (nigrum), kalii hydroxidum, pro capsula.

Articles (1)

Litfulo 50 mg, Hartkapseln
Kapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
11/09/2026
Professional SmPC
Français
11/09/2026
Professional SmPC
Italien
11/09/2026
Patient information leaflet
Allemand
01/05/2025
Patient information leaflet
Français
01/05/2025
Patient information leaflet
Italien
01/05/2025

Detailed composition

Substance Quantity Type Category
ritlecitinibum
50.0 MG Substance Wirkstoff (Principe actif)
ritlecitinibi tosilas
- Substance WIZUS
cellulosum microcristallinum
- Substance HNIDK
lactosum monohydricum
21.269 MG Substance HBESI
crospovidonum
- Substance HNIDK
glyceroli dibehenas
- Substance HNIDK
hypromellosum
- Substance HNIDK
E 171
- Substance FNIDK
E 172 (flavum)
- Substance FTODK
E 133
- Substance FIMDK
lacca
- Substance HNIDK
propylenglycolum
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
ammoniae solutio concentrata
- Substance HNIDK
E 172 (nigrum)
- Substance FTODK
kalii hydroxidum
- Substance HNIDK

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
69695
Drug name
Litfulo, Hartkapseln
Galenic form
KAHA
ATC Code
L04AF08
Authorization status
Z
Dispensation category
B
First authorization
03/02/2025
Authorization expiration date
02/02/2030
IT number
07.15.0.
Domain
Human medicine
Field of application
Behandlung von schwerer Alopecia areata (≥50 % der Kopfhaut betroffen) bei Erwachsenen bis maximal 65 Jahre und Jugendlichen ab einem Alter von 12 Jahren, die für eine systemische Therapie in Frage kommen

Packaging details

Description (FR)
LITFULO caps 50 mg 30 pce
Description (DE)
LITFULO Kaps 50 mg 30 Stk
Market launch
03/02/2025
Narcotic (BTM)
No
Buy us a coffee Explore the data